BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.59
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained a Market Perform rating on CytomX Therapeutics (NASDAQ:CTMX) and increased the price target from $3.25 to $3.59.
May 09, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained its Market Perform rating on CytomX Therapeutics and raised the price target from $3.25 to $3.59.
The increase in price target by BMO Capital suggests a positive outlook on the stock's future performance, potentially leading to increased investor interest and a short-term uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100